Literature DB >> 2881428

Combination of psychotherapy and drugs in the treatment of neurosis. A controlled comparison of bromazepam and thioridazine.

S J Dencker, B G Fasth.   

Abstract

Eighty out-patients with neurotic disorders were studied in an integrated treatment model combining psychotherapy and psychotropics in a "conjoint marital therapy" setting. The spouses, who seemed a healthy group, were used as reporters, as controls and as participants in the psychotherapy. The pharmacological trial was a double-blind, cross-over study, comparing bromazepam and thioridazine after a placebo period. Bromazepam was more effective in controlling different anxiety symptoms and demonstrated more potent activating properties than thioridazine. Hostility symptoms, however, responded better to thioridazine. These findings were confirmed by ratings performed by patients, spouses and the investigator. Differences in drug preference and drop-out rate showed the same tendency. Nine weeks' continuous treatment did not change the differences found in the cross-over study. No pharmacological rebound symptoms were observed after drug withdrawal. The personality of the spouses was related to the outcome in the patients. Moreover, there was an obvious positive interaction between the psychotherapy given and the drug treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2881428     DOI: 10.1111/j.1600-0447.1986.tb06286.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  2 in total

1.  The course of psychiatric illness in primary care patients. A 1-year follow-up.

Authors:  L Hansson; L Borgquist; P Nettelbladt; G Nordström
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1994-02       Impact factor: 4.328

2.  Test characteristics of the Hopkins Symptom Check List-25 (HSCL-25) in Sweden, using the Present State Examination (PSE-9) as a caseness criterion.

Authors:  P Nettelbladt; L Hansson; C G Stefansson; L Borgquist; G Nordström
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1993-07       Impact factor: 4.328

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.